WAVE Life Sciences (NASDAQ:WVE – Get Free Report) last posted its quarterly earnings results on Monday, November 10th. WAVE Life Sciences had a negative net margin of 111.64% and a negative return on equity of 75.61%. As a group, equities analysts predict that WAVE Life Sciences will post -1.14 earnings per share for the current fiscal year. WAVE Life Sciences Company Profile(Get Free Report)WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Further ReadingReceive News & Ratings for WAVE Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WAVE Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.